Pharmacokinetic analysis of ceftazidime and cefazolin in the treatment of continuous ambulatory peritoneal dialysis-related peritonitis

• Published in: Renal failure Vol. 45; no. 2; p. 2285873
• Main Authors: Zhu, Weiping, Fang, Xueling, Zheng, Jing, Ke, Ying, He, Qiaolan, Cui, Tongxia, Chen, Bairong, Tian, Lin
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis Ltd 2023; Taylor & Francis; Taylor & Francis Group
• Subjects: Adult; Anti-Bacterial Agents - therapeutic use; Antibiotics; Anuria - etiology; Body weight; Cefazolin; Ceftazidime; Ceftazidime - pharmacokinetics; Ceftazidime - therapeutic use; Clinical Study; Dialysate; Dialysis Solutions; Effluents; Female; Hemodialysis; Humans; Liquid chromatography; Male; Mass spectroscopy; Middle Aged; Minimum inhibitory concentration; Peritoneal dialysis; Peritoneal Dialysis, Continuous Ambulatory - adverse effects; Peritoneal Dialysis, Continuous Ambulatory - methods; Peritoneum; Peritonitis; Peritonitis - drug therapy; Peritonitis - etiology; Pharmacokinetics; Prospective Studies; ceftazidime; Pharmacokinetics; cefazolin; peritonitis
• ISSN: 0886-022X; 1525-6049
• DOI: 10.1080/0886022X.2023.2285873

Peritoneal dialysis-related peritonitis (PDRP) presents a significant challenge for nephrologists. Continuous intraperitoneal cefazolin and ceftazidime are recommended for the treatment of peritonitis. However, some pharmacokinetic studies have shown that doses of 15-20 mg/kg/d may not achieve sufficient therapeutic levels. In this study, we investigated the pharmacokinetics of ceftazidime and cefazolin in patients with continuous ambulatory peritoneal dialysis-related peritonitis and compared the pharmacokinetic characteristics between traditional and modified treatment groups. From February 2017 to December 2019, 42 PDRP patients (17 males, 25 females; mean age: 50.7 ± 12.1 years; mean body weight: 60.9 ± 11.8 kg) were recruited for the study, all participants were anuric. Twenty patients were enrolled in the traditional group and treated with cefazolin (1.0 g) and ceftazidime (1.0 g) intraperitoneal administration once daily for 14 days. Twenty-two patients were enrolled in the modified group and received the same dose of antibiotics twice daily for the initial five days, followed by once daily for the subsequent nine days. Serum and dialysate samples were collected after days 1, 2, 3, 5, 7, 10, and 14 and analyzed liquid chromatography-mass spectrometry. In the traditional group, the highest and lowest serum concentrations of ceftazidime were 35.9 and 21.7 µg/mL, respectively. The highest concentration of cefazolin was 54.6 µg/mL on day 5 and the lowest concentration was 30.4 µg/mL on day 1. In the modified group, the highest and lowest serum concentrations of ceftazidime were 102.2 and 54.8 µg/mL, respectively. The highest concentration of cefazolin was 141.7 µg/mL and the lowest concentration was 79.8 µg/mL. All antibiotic concentrations were above the minimum inhibitory concentration (MIC) level (8 µg/mL of ceftazidime and 2 µg/mL of cefazolin) throughout the treatment period. However, on day 1, the concentration of ceftazidime in the third bag of dialysate effluent from the traditional group fell below the MIC level. Despite remaining above the MIC, cefazolin concentration was consistently lower in the third bag of dialysate effluent from the traditional group throughout the treatment period. Intraperitoneal administration of cefazolin and ceftazidime at a dose of 1 g twice daily for 5 days and then once daily for the rest of the treatment period ensured adequate therapeutic levels of antibiotics for treating anuric PDRP patients.